论文部分内容阅读
目的观察曲美他嗪治疗冠心病心力衰竭的临床疗效、安全性及对血浆脑钠肽的影响。方法108例慢性心力衰竭患者随机分为两组,对照组予以血管紧张素转换酶抑制剂、β受体阻滞剂、正性肌力药物、利尿剂及血管扩张剂等药物治疗,治疗组在此基础上加用曲美他嗪20 mg,3次/d口服,治疗6个月后对比观察两组临床症状、左室射血分数、左室舒张末期内径、6 min步行距离、血浆脑钠肽的变化情况。结果治疗组各项指标均明显改善,患者生活质量明显提高。结论在常规抗心力衰竭治疗基础上加用曲美他嗪治疗冠心病心力衰竭安全有效,且能改善冠心病心力衰竭患者的生活质量,具有重要的临床意义。
Objective To observe the clinical efficacy and safety of trimetazidine in the treatment of heart failure with coronary heart disease and its effect on plasma brain natriuretic peptide. Methods A total of 108 patients with chronic heart failure were randomly divided into two groups. Patients in the control group were treated with drugs such as angiotensin converting enzyme inhibitors, β-blockers, inotropic drugs, diuretics and vasodilators. On the basis of trimetazidine plus 20 mg, 3 times / d orally, after 6 months of treatment, the clinical symptoms, left ventricular ejection fraction, left ventricular end-diastolic diameter, walking distance 6 min, plasma brain natriuretic peptide Peptide changes. Results The treatment group indicators were significantly improved, patients with significantly improved quality of life. Conclusion Trimetazidine combined with trimetazidine in the treatment of heart failure is safe and effective, and can improve the quality of life in patients with coronary heart disease and heart failure. It is of great clinical significance.